Griffin P. Carter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Griffin P. Carter has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Mark A. Katz
Department of Molecular Genetics & Microbiology, Duke University School of Medicine, Durham, NC 27710, USA
12 shared publications - Matthias Gromeier
Department of Molecular Genetics & Microbiology, Duke University School of Medicine, Durham, NC 27710, USA
12 shared publications - Michael Clavon Brown
Department of Neurosurgery, Duke University School of Medicine, Durham, NC 27710, USA
12 shared publications - Zachary P. McKay
Department of Neurosurgery, Duke University School of Medicine, Durham, NC 27710, USA
12 shared publications - Andrea L. Ludwig
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
11 shared publications - Annick Desjardins
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, USA
11 shared publications
Latest Publications
- Open Access
Regulation and Characterization of the Cex system of enteric pathogens: a pathway for the lipidation and secretion of noncanoncial bacterial lipoproteins
CexE is an outer membrane lipoprotein of enterotoxigenic Escherichia coli (ETEC); one of the most prevalent etiological agents of diarrheal disease. Homologs of CexE are present in enteroaggregative E. coli, Citrobacter rodentium, and other enteropathogens. We have previously shown that expression of CexE is dependent upon Rns, the master virulence regulator of ETEC and a member of the AraC/XylS superfamily of transcription factors. In this study we report that the expression of cexD and cexPABC, the genes required for lipidation and delivery of CexE to the outer leaflet of the outer membrane, are also Rns-dependent. Although cexE and cexPABC are arranged in the same orientation, they are separated by an intergenic region sufficiently large to accommodate a promoter and transcription factor binding sites. Nevertheless, expression of the four gene cluster does not originate within the intergenic region. Rather, cexPABC are expressed from the Rns-dependent cexE promoter. The remaining gene of the system, cexD, is monocistronic and expressed from its own Rns-dependent promoter. Mutagenesis of a predicted Rns binding site upstream of cexD abolished Rns binding to a cexD promoter fragment in vitro and activation of the promoter in vivo. CexD is a novel bacterial acyltransferase. Unlike canonical bacterial acyltransferases that lipidate amino-terminal cysteines, CexD attaches a lipid to the amino-terminal glycine of CexE. Lipidation must occur in the periplasm because topological mapping revealed that CexD has six transmembrane domains with both its amino-terminus and enzymatic domain in the periplasm. We further show that CexD is required for CexE localization to the outer leaflet of the outer membrane and that a cexD mutant of C. rodentium is attenuated in a murine model. These findings further define the Rns virulence regulon, the enzymology of a noncanonical acyltranferase and its contributions to pathogenicity.
Open AccessRegulation and Characterization of the Cex system of enteric pathogens: a pathway for the lipidation and secretion of noncanoncial bacterial lipoproteins
CexE is an outer membrane lipoprotein of enterotoxigenic Escherichia coli (ETEC); one of the most prevalent etiological agents of diarrheal disease. Homologs of CexE are present in enteroaggregative E. coli, Citrobacter rodentium, and other enteropathogens. We have previously shown that expression of CexE is dependent upon Rns, the master virulence regulator of ETEC and a member of the AraC/XylS superfamily of transcription factors. In this study we report that the expression of cexD and cexPABC, the genes required for lipidation and delivery of CexE to the outer leaflet of the outer membrane, are also Rns-dependent. Although cexE and cexPABC are arranged in the same orientation, they are separated by an intergenic region sufficiently large to accommodate a promoter and transcription factor binding sites. Nevertheless, expression of the four gene cluster does not originate within the intergenic region. Rather, cexPABC are expressed from the Rns-dependent cexE promoter. The remaining gene of the system, cexD, is monocistronic and expressed from its own Rns-dependent promoter. Mutagenesis of a predicted Rns binding site upstream of cexD abolished Rns binding to a cexD promoter fragment in vitro and activation of the promoter in vivo. CexD is a novel bacterial acyltransferase. Unlike canonical bacterial acyltransferases that lipidate amino-terminal cysteines, CexD attaches a lipid to the amino-terminal glycine of CexE. Lipidation must occur in the periplasm because topological mapping revealed that CexD has six transmembrane domains with both its amino-terminus and enzymatic domain in the periplasm. We further show that CexD is required for CexE localization to the outer leaflet of the outer membrane and that a cexD mutant of C. rodentium is attenuated in a murine model. These findings further define the Rns virulence regulon, the enzymology of a noncanonical acyltranferase and its contributions to pathogenicity.
- Open Access
Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris
Owing to pivotal roles in CNS debris clearance and homeostasis, microglia are central targets for the therapy of neurodegenerative diseases. Intricate proximity to neurons, the inherent danger of neuroimmune toxicity, and intrinsically high plasticity and adaptability, impose high hurdles on microglia modulation. Attenuated viruses are being tested extensively against CNS malignancies (i.e., cancer virotherapy); yet, aside from viral vector-mediated payload delivery, virotherapy for non-neoplastic CNS disease remains unexplored. Here we report disseminated targeting of microglia with the highly attenuated polio:rhinovirus chimera, PVSRIPO, that culminated in profound, durable microglia reprogramming. This phenotype, rooted in extended cytoplasmic viral (v)RNA replication, was non-cytopathogenic and did not yield virus progeny or dissemination. vRNA replication in microglia triggered selective interferon (IFN) regulatory factor (IRF) 3/IRF7 transcriptional programs in the relative absence of NFκB-driven proinflammatory cytokine responses and elicited robust phagocytosis of both tumor cells and amyloid-beta. Targeting of microglia with PVSRIPO mediated immunotherapy in a mouse glioma model and the clearance of oligomeric amyloid-beta deposits in an injectable model of neurotoxic amyloid accumulation. This work identifies attenuated virotherapy as an approach to safely and effectively invigorate microglia function in immune surveillance and neurotoxic debris clearance.
Open AccessViral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris
Owing to pivotal roles in CNS debris clearance and homeostasis, microglia are central targets for the therapy of neurodegenerative diseases. Intricate proximity to neurons, the inherent danger of neuroimmune toxicity, and intrinsically high plasticity and adaptability, impose high hurdles on microglia modulation. Attenuated viruses are being tested extensively against CNS malignancies (i.e., cancer virotherapy); yet, aside from viral vector-mediated payload delivery, virotherapy for non-neoplastic CNS disease remains unexplored. Here we report disseminated targeting of microglia with the highly attenuated polio:rhinovirus chimera, PVSRIPO, that culminated in profound, durable microglia reprogramming. This phenotype, rooted in extended cytoplasmic viral (v)RNA replication, was non-cytopathogenic and did not yield virus progeny or dissemination. vRNA replication in microglia triggered selective interferon (IFN) regulatory factor (IRF) 3/IRF7 transcriptional programs in the relative absence of NFκB-driven proinflammatory cytokine responses and elicited robust phagocytosis of both tumor cells and amyloid-beta. Targeting of microglia with PVSRIPO mediated immunotherapy in a mouse glioma model and the clearance of oligomeric amyloid-beta deposits in an injectable model of neurotoxic amyloid accumulation. This work identifies attenuated virotherapy as an approach to safely and effectively invigorate microglia function in immune surveillance and neurotoxic debris clearance.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Table S3. Top-20 differentially expressed genes in tumor-infiltrating T cell subsets (extended data relating to Figure 5D).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Table S3. Top-20 differentially expressed genes in tumor-infiltrating T cell subsets (extended data relating to Figure 5D).
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S2. Differences in gene expression and hallmark pathways between single-site (IT or CPLI) and dual-site (IT plus CPLI) treatment cohorts compared to mock treatment as shown.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S2. Differences in gene expression and hallmark pathways between single-site (IT or CPLI) and dual-site (IT plus CPLI) treatment cohorts compared to mock treatment as shown.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S4. a,b, Extended data relating to Figure 4C-G. MECA-79+ HEV, which harbor (-)strand vRNA in CT2A glioma-bearing mice after dual site (IT+CPLI) PVSRIPO, stain positive for the poliovirus receptor CD155.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S4. a,b, Extended data relating to Figure 4C-G. MECA-79+ HEV, which harbor (-)strand vRNA in CT2A glioma-bearing mice after dual site (IT+CPLI) PVSRIPO, stain positive for the poliovirus receptor CD155.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S1. Extended data on cLN phenotypes after IT PVSRIPO infusion in CT2A mouse glioma.
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S1. Extended data on cLN phenotypes after IT PVSRIPO infusion in CT2A mouse glioma.
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. In this study, we identify type-I interferon (IFNI) signaling in glioma-draining cervical lymph nodes as a mediator of IT polio virotherapy. Transient IFNI signaling after IT administration was rescued by cervical perilymphatic infusion (CPLI) virotherapy, targeting cervical lymph nodes directly. Dual-site (IT plus CPLI) virotherapy induced profound inflammatory reprogramming of cervical lymph nodes, enhanced viral RNA replication and IFNI signaling in dendritic cells and high endothelial venules, augmented antiglioma efficacy in mice, and was associated with T-cell activation in patients with recurrent glioblastoma. A phase II clinical trial of IT plus CPLI polio virotherapy is ongoing (NCT06177964). This study implicates the lymphatic system as a virotherapy target and demonstrates that CPLI virotherapy has the potential to complement brain tumor immunotherapy.See related Spotlight by Kaufman, p. 182
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Tumor-draining lymph nodes are a pivotal site for antitumor T-cell priming. However, their mechanistic roles in cancer immune surveillance and immunotherapy response remain poorly defined. Intratumor (IT) virotherapy generates antitumor T-cell immunity through multifaceted engagement of innate antiviral inflammation. In this study, we identify type-I interferon (IFNI) signaling in glioma-draining cervical lymph nodes as a mediator of IT polio virotherapy. Transient IFNI signaling after IT administration was rescued by cervical perilymphatic infusion (CPLI) virotherapy, targeting cervical lymph nodes directly. Dual-site (IT plus CPLI) virotherapy induced profound inflammatory reprogramming of cervical lymph nodes, enhanced viral RNA replication and IFNI signaling in dendritic cells and high endothelial venules, augmented antiglioma efficacy in mice, and was associated with T-cell activation in patients with recurrent glioblastoma. A phase II clinical trial of IT plus CPLI polio virotherapy is ongoing (NCT06177964). This study implicates the lymphatic system as a virotherapy target and demonstrates that CPLI virotherapy has the potential to complement brain tumor immunotherapy.See related Spotlight by Kaufman, p. 182
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S6. a-c, Extended data relating to Figure 5. Umap of snRNAseq of combined samples from three intervals (see Figure 5D); individual cell types are labeled (a). Umap of cells identified as T cells in a; individual subsets are labeled (see Supplementary Table S2 for extended data) (b). Proportion of cell types identified in a by time point (c). d, e, Gating strategy used (extended data relating to Figure 5E, F).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S6. a-c, Extended data relating to Figure 5. Umap of snRNAseq of combined samples from three intervals (see Figure 5D); individual cell types are labeled (a). Umap of cells identified as T cells in a; individual subsets are labeled (see Supplementary Table S2 for extended data) (b). Proportion of cell types identified in a by time point (c). d, e, Gating strategy used (extended data relating to Figure 5E, F).
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Antibodies used in flow-cytometry analyses
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Antibodies used in flow-cytometry analyses
- Open Access
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S3. Dual-site (IT+CPLI) PVSRIPO in CT2A-bearing mice changes immune cell composition in cLN (extended data relating to Figure 3).
- 3 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
Supplementary Figure S3. Dual-site (IT+CPLI) PVSRIPO in CT2A-bearing mice changes immune cell composition in cLN (extended data relating to Figure 3).